scholarly journals Pancreatic endocrine tumor

2021 ◽  
Author(s):  
Mohammad Niknejad
Keyword(s):  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor

scholarly journals ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes

2012 ◽  
Vol 95 (2) ◽  
pp. 98-119 ◽  
Author(s):  
Robert T. Jensen ◽  
Guillaume Cadiot ◽  
Maria L. Brandi ◽  
Wouter W. de Herder ◽  
Gregory Kaltsas ◽  
...  
Keyword(s):  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Neuroendocrine Neoplasms ◽  
Consensus Guidelines

Imaging for Pancreatic Endocrine Tumor Localization: Recent Advances

2015 ◽  
pp. 268-281 ◽  
Author(s):  
Murray Orbuch ◽  
John L. Doppman ◽  
Doris B. Strader ◽  
Vitaly A. Fishbeyn ◽  
Richard V. Benya ◽  
...  
Keyword(s):  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Tumor Localization ◽  
Recent Advances

Multihormonal Pancreatic Endocrine Tumor in a Dog with Duodenal Ulcers and Hypertrophic Gastropathy

1988 ◽  
Vol 25 (3) ◽  
pp. 237-239 ◽  
Author(s):  
T. R. Boosinger ◽  
C. A. Zerbe ◽  
J. H. Grabau ◽  
J. M. Pletcher
Keyword(s):  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Duodenal Ulcers ◽  
Hypertrophic Gastropathy

EUS-FNA Microsatellite Loss Predicts Pancreatic Endocrine Tumor Aggressiveness

2005 ◽  
Vol 61 (5) ◽  
pp. AB286 ◽  
Author(s):  
Laurentia Nodit ◽  
Kevin M. McGrath ◽  
Debra Brody ◽  
N.P. Ohori ◽  
Karen E. Schoedel ◽  
...  
Keyword(s):  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Tumor Aggressiveness

Pancreatic Endocrine Tumor in Japan

Pancreas ◽  
2004 ◽  
Vol 28 (3) ◽  
pp. 247-252 ◽  
Author(s):  
Ryuichiro Doi ◽  
Izumi Komoto ◽  
Yoshio Nakamura ◽  
Junichiro Kawamura ◽  
Koji Fujimoto ◽  
...  
Keyword(s):  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

2008 ◽  
Vol 26 (20) ◽  
pp. 3403-3410 ◽  
Author(s):  
Matthew H. Kulke ◽  
Heinz-Josef Lenz ◽  
Neal J. Meropol ◽  
James Posey ◽  
David P. Ryan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Objective Response ◽  
Pancreatic Neuroendocrine Tumor ◽  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Tumor Patients ◽  
Patient Reported

Purpose Standard cytotoxic chemotherapy has limited efficacy in metastatic neuroendocrine tumor patients. Neuroendocrine tumors express vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Sunitinib malate, an oral tyrosine kinase inhibitor, has activity against VEGFRs as well as platelet-derived growth factor receptors, stem-cell factor receptor, glial cell line–derived neurotrophic factor, and FMS-like tyrosine kinase-3. We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients. Patients and Methods Patients were treated with repeated 6-week cycles of oral sunitinib (50 mg/d for 4 weeks, followed by 2 weeks off treatment). Patients were observed for response, survival, and adverse events. Patient-reported outcomes were assessed. Results Among 109 enrolled patients, 107 received sunitinib (carcinoid, n = 41; pancreatic endocrine tumor, n = 66). Overall objective response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients), and 68% (45 of 66 patients) had stable disease (SD). Among carcinoid patients, ORR was 2.4% (one of 41 patients), and 83% (34 of 41 patients) had SD. Median time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months in carcinoid patients. One-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in carcinoid patients. No significant differences from baseline in patient-reported quality of life or fatigue were observed during treatment. Conclusion Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this nonrandomized study. Randomized trials of sunitinib in patients with neuroendocrine tumors are warranted.

Sign in / Sign up

Export Citation Format

Share Document